{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["denosumab", "giant cell tumour of bone", "osteonecrosis of the jaw", "ozono therapy", "surgery"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "32661185", "DateCompleted": {"Year": "2021", "Month": "07", "Day": "19"}, "DateRevised": {"Year": "2021", "Month": "07", "Day": "19"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": ["e000663", "10.1136/esmoopen-2019-000663"], "Journal": {"ISSN": "2059-7029", "JournalIssue": {"Volume": "5", "Issue": "4", "PubDate": {"Year": "2020", "Month": "Jul"}}, "Title": "ESMO open", "ISOAbbreviation": "ESMO Open"}, "ArticleTitle": "Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.", "Abstract": {"AbstractText": ["Giant cell tumour of bone (GCTB) is a rare tumour, generally managed with surgery. Treatment of the very rare unresectable advanced/metastatic GCTB is challenging and denosumab is the only current available medical option, an anti-RANKL monoclonal antibody inhibiting osteolysis. An uncommon but severe and treatment-limiting adverse event of denosumab is the osteonecrosis of the jaw (ONJ). The clinical management of GCTB patients stopping denosumab for medication-related (MR)-ONJ and the possible reintroduction of denosumab after MR-ONJ resolution is matter of debate. We performed a retrospective study to describe the incidence, clinical features and outcome of MR-ONJ in unresectable GCTB patients treated with denosumab at our Institution.", "Retrospective, single-institutional study.", "Adult patients receiving denosumab as antineoplastic therapy for GCTB and experiencing MR-ONJ at Fondazione IRCCS Istituto Nazionale Tumori of Milan between January 2008 and July 2019.", "Incidence, time of onset and clinical features of MR-ONJ.", "29 patients with locally advanced and/or metastatic GCTB treated with denosumab were identified. At a median follow-up of 70 months (range 1-125), 4 (13.8%) patients experienced MR-ONJ while on treatment, after 125, 119, 85 and 41 months of denosumab, respectively. All patients showed an ongoing tumour stabilisation with denosumab at the MR-ONJ onset and in all cases denosumab was stopped. All four patients were treated with ozone therapy. Two are waiting for surgery, two were already operated on. Both of them experienced disease progression and were thus rechallenged with denosumab. One is still on therapy after 25 months. The other had an MR-ONJ relapse after 39 months and was treated again with ozone therapy and surgery. She is under surveillance, GCTB being currently stable.", "A clinical algorithm of denosumab rechallenge after complete resolution of MR-ONJ in progressing GCTB patients should be prospectively validated."], "CopyrightInformation": "\u00a9 Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology."}, "AuthorList": [{"Identifier": ["0000-0002-8999-2899"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Raimondi", "ForeName": "Alessandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Simeone", "ForeName": "Noemi", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Head and Neck Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Guzzo", "ForeName": "Marco", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Dental Team, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Maniezzo", "ForeName": "Massimo", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Soft Tissue and Bone Pathology, Histopathology and Pediatric Pathology Unit, Diagnostic Pathology and Laboratory Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Collini", "ForeName": "Paola", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Morosi", "ForeName": "Carlo", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Greco", "ForeName": "Francesca Gabriella", "Initials": "FG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}], "LastName": "Frezza", "ForeName": "Anna Maria", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy."}, {"Identifier": [], "Affiliation": "Department of Oncology and Hemato-oncology, University of Milan, Milano, Lombardia, Italy."}], "LastName": "Casali", "ForeName": "Paolo G", "Initials": "PG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy silvia.stacchiotti@istitutotumori.mi.it."}], "LastName": "Stacchiotti", "ForeName": "Silvia", "Initials": "S"}], "PublicationTypeList": ["Case Reports", "Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "ESMO Open", "NlmUniqueID": "101690685", "ISSNLinking": "2059-7029"}, "ChemicalList": [{"RegistryNumber": "4EQZ6YO2HI", "NameOfSubstance": "Denosumab"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Bone Neoplasms"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Denosumab"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Giant Cell Tumor of Bone"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemically induced"], "DescriptorName": "Jaw Diseases"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["chemically induced"], "DescriptorName": "Osteonecrosis"}, {"QualifierName": [], "DescriptorName": "Retrospective Studies"}], "CoiStatement": "Competing interests: SS, AMF, AR, NS: institutional research funding from Pfizer, Novartis, Glaxo. PGC: grants and personal fees from Bayer, Glaxo, Novartis."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Behjati S, Tarpey PS, Presneau N, et al. . Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45:1479\u201382. 10.1038/ng.2814", "ArticleIdList": ["10.1038/ng.2814", "PMC3839851", "24162739"]}, {"Citation": "Mendenhall WM, Zlotecki RA, Scarborough MT, et al. . Giant cell tumor of bone. Am J Clin Oncol 2006;29:96\u20139. 10.1097/01.coc.0000195089.11620.b7", "ArticleIdList": ["10.1097/01.coc.0000195089.11620.b7", "16462511"]}, {"Citation": "Alberghini M, Kliskey K, Krenacs T, et al. . Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010;456:97\u2013103. 10.1007/s00428-009-0863-2", "ArticleIdList": ["10.1007/s00428-009-0863-2", "20012988"]}, {"Citation": "W\u00fclling M, Engels C, Jesse N, et al. . The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001;127:467\u201374. 10.1007/s004320100234", "ArticleIdList": ["10.1007/s004320100234", "11501745"]}, {"Citation": "Jaffe H, Lichstentein L, Portis R. Giant cell tumor of bone. its pathological appearance, grading, supposed variants and treatment. Arch Pathol 1940;30:993\u20131031."}, {"Citation": "Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 2006;30:484\u20139. 10.1007/s00264-006-0215-7", "ArticleIdList": ["10.1007/s00264-006-0215-7", "PMC3172738", "17013643"]}, {"Citation": "Branstetter DG, Nelson SD, Manivel JC, et al. . Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415\u201324. 10.1158/1078-0432.CCR-12-0578", "ArticleIdList": ["10.1158/1078-0432.CCR-12-0578", "22711702"]}, {"Citation": "Rutkowski P, Gaston L, Borkowska A, et al. . Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Eur J Surg Oncol 2018;44:1384\u201390. 10.1016/j.ejso.2018.03.020", "ArticleIdList": ["10.1016/j.ejso.2018.03.020", "29650420"]}, {"Citation": "Chawla S, Blay J-Y, Rutkowski P, et al. . Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 2019;20:1719\u201329. 10.1016/S1470-2045(19)30663-1", "ArticleIdList": ["10.1016/S1470-2045(19)30663-1", "31704134"]}, {"Citation": "Khan AA, Morrison A, Kendler DL, et al. . Case-Based review of osteonecrosis of the jaw (ONJ) and application of the International recommendations for management from the International Task force on ONJ. J Clin Densitom 2017;20:8\u201324. 10.1016/j.jocd.2016.09.005", "ArticleIdList": ["10.1016/j.jocd.2016.09.005", "27956123"]}, {"Citation": "Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA, et al. . Medication-Related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:117\u201335. 10.1016/j.oooo.2018.09.008", "ArticleIdList": ["10.1016/j.oooo.2018.09.008", "30393090"]}, {"Citation": "Palmerini E, Chawla NS, Ferrari S, et al. . Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer 2017;76:118\u201324. 10.1016/j.ejca.2017.01.028", "ArticleIdList": ["10.1016/j.ejca.2017.01.028", "28324746"]}, {"Citation": "Yamada S-I, Kurita H, Kondo E, et al. . Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. Clin Oral Investig 2019;23:3203\u201311. 10.1007/s00784-018-2743-0", "ArticleIdList": ["10.1007/s00784-018-2743-0", "30406491"]}, {"Citation": "Ripamonti CI, Cislaghi E, Mariani L, et al. . Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol 2011;47:185\u201390. 10.1016/j.oraloncology.2011.01.002", "ArticleIdList": ["10.1016/j.oraloncology.2011.01.002", "21310650"]}, {"Citation": "Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, et al. . Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese allied Committee on osteonecrosis of the jaw. J Bone Miner Metab 2017;35:6\u201319. 10.1007/s00774-016-0810-7", "ArticleIdList": ["10.1007/s00774-016-0810-7", "28035494"]}, {"Citation": "Hoefert S, Yuan A, Munz A, et al. . Clinical course and therapeutic outcomes of operatively and non-operatively managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniomaxillofac Surg 2017;45:570\u20138. 10.1016/j.jcms.2017.01.013", "ArticleIdList": ["10.1016/j.jcms.2017.01.013", "28238559"]}, {"Citation": "Ruggiero SL, Dodson TB, Fantasia J, et al. . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938\u201356. 10.1016/j.joms.2014.04.031", "ArticleIdList": ["10.1016/j.joms.2014.04.031", "25234529"]}, {"Citation": "Chawla S, Henshaw R, Seeger L, et al. . Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14:901\u20138. 10.1016/S1470-2045(13)70277-8", "ArticleIdList": ["10.1016/S1470-2045(13)70277-8", "23867211"]}, {"Citation": "Martin-Broto J, Cleeland CS, Glare PA, et al. . Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol 2014;53:1173\u20139. 10.3109/0284186X.2014.910313", "ArticleIdList": ["10.3109/0284186X.2014.910313", "24834795"]}, {"Citation": "Shapiro CL, Moriarty JP, Dusetzina S, et al. . Cost-Effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol 2017;35:3949\u201355. 10.1200/JCO.2017.73.7437", "ArticleIdList": ["10.1200/JCO.2017.73.7437", "PMC5721226", "29023215"]}, {"Citation": "Stopeck AT, Fizazi K, Body J-J, et al. . Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 2016;24:447\u201355. 10.1007/s00520-015-2904-5", "ArticleIdList": ["10.1007/s00520-015-2904-5", "PMC4669370", "26335402"]}, {"Citation": "Fizazi K, Carducci M, Smith M, et al. . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813\u201322. 10.1016/S0140-6736(10)62344-6", "ArticleIdList": ["10.1016/S0140-6736(10)62344-6", "PMC3090685", "21353695"]}, {"Citation": "Henry DH, Costa L, Goldwasser F, et al. . Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125\u201332. 10.1200/JCO.2010.31.3304", "ArticleIdList": ["10.1200/JCO.2010.31.3304", "21343556"]}, {"Citation": "Saad F, Brown JE, Van Poznak C, et al. . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341\u20137. 10.1093/annonc/mdr435", "ArticleIdList": ["10.1093/annonc/mdr435", "21986094"]}, {"Citation": "Lipton A, Fizazi K, Stopeck AT, et al. . Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082\u201392. 10.1016/j.ejca.2012.08.002", "ArticleIdList": ["10.1016/j.ejca.2012.08.002", "22975218"]}, {"Citation": "Coleman R, Body JJ, Aapro M, et al. . Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014;25 Suppl 3:iii124\u201337. 10.1093/annonc/mdu103", "ArticleIdList": ["10.1093/annonc/mdu103", "24782453"]}, {"Citation": "Di Fede O, Panzarella V, Mauceri R, et al. . The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018;2018:1\u201310. 10.1155/2018/2684924", "ArticleIdList": ["10.1155/2018/2684924", "PMC6164200", "30306086"]}, {"Citation": "Khan AA, Morrison A, Hanley DA, et al. . Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3\u201323. 10.1002/jbmr.2405", "ArticleIdList": ["10.1002/jbmr.2405", "25414052"]}, {"Citation": "Hellstein JW, Adler RA, Edwards B, et al. . Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American dental association Council on scientific Affairs. J Am Dent Assoc 2011;142:1243\u201351. 10.14219/jada.archive.2011.0108", "ArticleIdList": ["10.14219/jada.archive.2011.0108", "22041409"]}, {"Citation": "Otto S, Pautke C, Van den Wyngaert T, et al. . Medication-Related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018;69:177\u201387. 10.1016/j.ctrv.2018.06.007", "ArticleIdList": ["10.1016/j.ctrv.2018.06.007", "30055439"]}, {"Citation": "Pittman K, Antill YC, Goldrick A, et al. . Denosumab: prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol 2017;13:266\u201376. 10.1111/ajco.12517", "ArticleIdList": ["10.1111/ajco.12517", "27862983"]}, {"Citation": "Badros A, Terpos E, Katodritou E, et al. . Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008;26:5904\u20139. 10.1200/JCO.2008.16.9300", "ArticleIdList": ["10.1200/JCO.2008.16.9300", "19018084"]}, {"Citation": "Mak IWY, Evaniew N, Popovic S, et al. . A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 2014;96:e127. 10.2106/JBJS.M.01332", "ArticleIdList": ["10.2106/JBJS.M.01332", "25100780"]}, {"Citation": "Wang HD, Boyce AM, Tsai JY, et al. . Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab 2014;99:891\u20137. 10.1210/jc.2013-3081", "ArticleIdList": ["10.1210/jc.2013-3081", "PMC3942242", "24423331"]}, {"Citation": "Brodowicz T, Hemetsberger M, Windhager R. Denosumab for the treatment of giant cell tumor of the bone. Future Oncol 2015;11:1881\u201394. 10.2217/fon.15.94", "ArticleIdList": ["10.2217/fon.15.94", "26161925"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "2", "Day": "3"}, {"Year": "2020", "Month": "3", "Day": "20"}, {"Year": "2020", "Month": "3", "Day": "23"}, {"Year": "2020", "Month": "7", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32661185", "PMC7359187", "10.1136/esmoopen-2019-000663", "S2059-7029(20)32636-3"]}}], "PubmedBookArticle": []}